Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma

Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: c8dfc6757df69579e755a864d43f7bd3ad4483b4
First added on: Feb 08, 2025